Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.

Cancer chemotherapy and pharmacology - 1 Jan 2011

Gounder Mrinal M, Maki Robert G

Abstract excerpt

Small molecule kinase inhibitors have irrevocably altered cancer treatment. March 2010 marks the 10th anniversary of using imatinib in gastrointestinal stromal tumors (GIST), a cardinal example of the utility of such targeted therapy in a solid tumor. Before imatinib, metastatic GIST was frustrating to treat due to its resistance to standard cytotoxic chemotherapy. Median survival for patients with metastatic...

Topics

Join the communities discussing this publication.

Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Gastrointestinal Stromal Tumors
Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Meta-Analysis as Topic

Randomized Controlled Trials as Topic

Receptor, Platelet-Derived Growth Factor alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 21116624
DOI: 10.1007/s00280-010-1526-3
PMCID: PMC3275340

Genes

KIT
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.PMID 21116624Read ↗

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal TumorsSemantic proximity Read ↗

Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.Semantic proximity Read ↗

Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review).Semantic proximity Read ↗

[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors].Semantic proximity Read ↗

Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read ↗

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.Semantic proximity Read ↗

[Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].Semantic proximity Read ↗

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.Semantic proximity Read ↗

Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategiesSemantic proximity Read ↗

Targeted Therapy for Advanced Gastrointestinal Stromal Tumors: Evolution and Future Directions.Semantic proximity Read ↗

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.Semantic proximity Read ↗

Secondary KIT mutations: the GIST of drug resistance and sensitivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.